Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Pozycja w akcjach #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Cena akcji
$3.12
Kapitalizacja rynkowa
$294.21M
Zmiana (1 dzień)
-3.26%
Zmiana (1 rok)
-51.10%
Kraj
US
Handel Myriad Genetics, Inc. (MYGN)

Kategoria

Cena MYGN z kapitalizacją rynkową B
Myriad Genetics, Inc. Myriad Genetics, Inc.
MYGN
$3.12
Kapitalizacja rynkowa Myriad Genetics, Inc.(MYGN)
Kapitalizacja rynkowa: $294.21M
Na dzień September 2026 spółka Myriad Genetics, Inc. ma kapitalizację rynkową wynoszącą $294.21M. Według naszych danych, czyni to Myriad Genetics, Inc. 16435th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Myriad Genetics, Inc. od 1995 do 2026
MYGN w porównaniu do 5 najpopularniejszych stocks
Cena za MYGN Aktywa B Kapitalizacja rynkowa B Wyniki
Myriad Genetics, Inc. Myriad Genetics, Inc.
$55,687.76 $294.21M
$5.260T +1,787,629.19%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$50,594.20 $294.21M
$4.779T +1,624,111.81%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$42,528.50 $294.21M
$4.017T +1,365,181.01%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$39,379.35 $294.21M
$3.719T +1,264,084.73%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$28,949.62 $294.21M
$2.734T +929,261.77%